blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2600889

EP2600889 - ANTI-LA ANTIBODIES AND THEIR USE FOR IMMUNOTARGETING [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  05.10.2018
Database last updated on 15.06.2024
FormerThe patent has been granted
Status updated on  27.10.2017
FormerGrant of patent is intended
Status updated on  12.07.2017
FormerExamination is in progress
Status updated on  16.12.2016
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): AL, IS		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
GEMoaB Monoclonals GmbH
Tatzberg 47
01307 Dresden / DE
[2017/12]
Former [2014/51]For all designated states
GEMoaB Monoclonals GmbH
Fiedlerstrasse 36
01307 Dresden / DE
Former [2013/24]For all designated states
Technische Universität Dresden
Mommsenstrasse 11
01062 Dresden / DE
Inventor(s)01 / BACHMANN, Michael
Dingesweg 4
65779 Kelkheim / DE
 [2013/24]
Representative(s)Kailuweit & Uhlemann Patentanwälte Partnerschaft mbB
Bamberger Straße 49
01187 Dresden / DE
[2017/48]
Former [2013/24]Kailuweit & Uhlemann Patentanwälte
Bamberger Straße 49
01187 Dresden / DE
Application number, filing date11743999.205.08.2011
[2017/48]
WO2011EP63539
Priority number, dateDE2010103901806.08.2010         Original published format: DE102010039018
[2013/24]
Filing languageDE
Procedural languageDE
PublicationType: A2 Application without search report
No.:WO2012017082
Date:09.02.2012
Language:DE
[2012/06]
Type: A2 Application without search report 
No.:EP2600889
Date:12.06.2013
Language:DE
The application published by WIPO in one of the EPO official languages on 09.02.2012 takes the place of the publication of the European patent application.
[2013/24]
Type: B1 Patent specification 
No.:EP2600889
Date:29.11.2017
Language:DE
[2017/48]
Search report(s)International search report - published on:EP30.08.2012
ClassificationIPC:A61K39/00, C07K16/28, C07K16/30
[2013/24]
CPC:
C07K16/30 (EP,US); C07K16/18 (EP,US); C07K16/2809 (EP,US);
C07K2317/24 (US); C07K2317/31 (EP,US); C07K2317/34 (EP,US);
C07K2317/54 (US); C07K2317/56 (US); C07K2317/565 (US);
C07K2317/622 (EP,US); C07K2317/626 (US); C07K2317/73 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/24]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ANTI-LA ANTIKÖRPER UND IHRE ANWENDUNG ZUM IMMUNOTARGETING[2013/24]
English:ANTI-LA ANTIBODIES AND THEIR USE FOR IMMUNOTARGETING[2013/24]
French:ANTICORPS ANTI-LA ET UTILISATION POUR UN IMMUNOCIBLAGE[2013/24]
Entry into regional phase04.02.2013National basic fee paid 
04.02.2013Designation fee(s) paid 
04.02.2013Examination fee paid 
Examination procedure04.02.2013Examination requested  [2013/24]
07.08.2013Amendment by applicant (claims and/or description)
06.06.2014Despatch of a communication from the examining division (Time limit: M06)
24.11.2014Reply to a communication from the examining division
15.10.2015Despatch of a communication from the examining division (Time limit: M06)
01.04.2016Reply to a communication from the examining division
17.08.2016Despatch of a communication from the examining division (Time limit: M06)
06.02.2017Reply to a communication from the examining division
13.07.2017Communication of intention to grant the patent
18.10.2017Fee for grant paid
18.10.2017Fee for publishing/printing paid
18.10.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  06.06.2014
Opposition(s)30.08.2018No opposition filed within time limit [2018/45]
Fees paidRenewal fee
03.06.2013Renewal fee patent year 03
03.06.2014Renewal fee patent year 04
03.06.2015Renewal fee patent year 05
31.05.2016Renewal fee patent year 06
07.06.2017Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU05.08.2011
AL29.11.2017
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
ES29.11.2017
FI29.11.2017
HR29.11.2017
IT29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
MK29.11.2017
MT29.11.2017
NL29.11.2017
PL29.11.2017
PT29.11.2017
RO29.11.2017
RS29.11.2017
SE29.11.2017
SI29.11.2017
SK29.11.2017
SM29.11.2017
TR29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
IS29.03.2018
AT05.08.2018
IE05.08.2018
LU05.08.2018
[2020/33]
Former [2020/31]HU05.08.2011
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
ES29.11.2017
FI29.11.2017
HR29.11.2017
IT29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
MK29.11.2017
MT29.11.2017
NL29.11.2017
PL29.11.2017
PT29.11.2017
RO29.11.2017
RS29.11.2017
SE29.11.2017
SI29.11.2017
SK29.11.2017
SM29.11.2017
TR29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
AT05.08.2018
IE05.08.2018
LU05.08.2018
Former [2020/27]HU05.08.2011
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
ES29.11.2017
FI29.11.2017
HR29.11.2017
IT29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
MT29.11.2017
NL29.11.2017
PL29.11.2017
PT29.11.2017
RO29.11.2017
RS29.11.2017
SE29.11.2017
SI29.11.2017
SK29.11.2017
SM29.11.2017
TR29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
AT05.08.2018
IE05.08.2018
LU05.08.2018
Former [2020/16]CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
ES29.11.2017
FI29.11.2017
HR29.11.2017
IT29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
MT29.11.2017
NL29.11.2017
PL29.11.2017
RO29.11.2017
RS29.11.2017
SE29.11.2017
SI29.11.2017
SK29.11.2017
SM29.11.2017
TR29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
AT05.08.2018
IE05.08.2018
LU05.08.2018
Former [2020/03]CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
ES29.11.2017
FI29.11.2017
HR29.11.2017
IT29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
MT29.11.2017
NL29.11.2017
PL29.11.2017
RO29.11.2017
RS29.11.2017
SE29.11.2017
SI29.11.2017
SK29.11.2017
SM29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
AT05.08.2018
IE05.08.2018
LU05.08.2018
Former [2019/33]CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
ES29.11.2017
FI29.11.2017
HR29.11.2017
IT29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
MT29.11.2017
NL29.11.2017
PL29.11.2017
RO29.11.2017
RS29.11.2017
SE29.11.2017
SI29.11.2017
SK29.11.2017
SM29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
IE05.08.2018
LU05.08.2018
Former [2019/21]CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
ES29.11.2017
FI29.11.2017
HR29.11.2017
IT29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
MT29.11.2017
NL29.11.2017
PL29.11.2017
RO29.11.2017
RS29.11.2017
SE29.11.2017
SI29.11.2017
SK29.11.2017
SM29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
LU05.08.2018
Former [2019/15]CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
ES29.11.2017
FI29.11.2017
HR29.11.2017
IT29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
MT29.11.2017
NL29.11.2017
PL29.11.2017
RO29.11.2017
RS29.11.2017
SE29.11.2017
SI29.11.2017
SK29.11.2017
SM29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
Former [2018/52]CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
ES29.11.2017
FI29.11.2017
HR29.11.2017
IT29.11.2017
LT29.11.2017
LV29.11.2017
MT29.11.2017
NL29.11.2017
PL29.11.2017
RO29.11.2017
RS29.11.2017
SE29.11.2017
SI29.11.2017
SK29.11.2017
SM29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
Former [2018/43]CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
ES29.11.2017
FI29.11.2017
HR29.11.2017
IT29.11.2017
LT29.11.2017
LV29.11.2017
MT29.11.2017
NL29.11.2017
PL29.11.2017
RO29.11.2017
RS29.11.2017
SE29.11.2017
SK29.11.2017
SM29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
Former [2018/40]CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
ES29.11.2017
FI29.11.2017
HR29.11.2017
IT29.11.2017
LT29.11.2017
LV29.11.2017
NL29.11.2017
PL29.11.2017
RO29.11.2017
RS29.11.2017
SE29.11.2017
SK29.11.2017
SM29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
Former [2018/39]CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
ES29.11.2017
FI29.11.2017
HR29.11.2017
IT29.11.2017
LT29.11.2017
LV29.11.2017
NL29.11.2017
PL29.11.2017
RS29.11.2017
SE29.11.2017
SK29.11.2017
SM29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
Former [2018/37]CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
ES29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
NL29.11.2017
PL29.11.2017
RS29.11.2017
SE29.11.2017
SK29.11.2017
SM29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
Former [2018/35]CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
ES29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
NL29.11.2017
RS29.11.2017
SE29.11.2017
SK29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
Former [2018/34]DK29.11.2017
ES29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
NL29.11.2017
RS29.11.2017
SE29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
Former [2018/24]ES29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
RS29.11.2017
SE29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
Former [2018/23]ES29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
RS29.11.2017
SE29.11.2017
NO28.02.2018
GR01.03.2018
Former [2018/22]ES29.11.2017
FI29.11.2017
LT29.11.2017
NO28.02.2018
Cited inInternational search[YD]US2005136050  (KUFER PETER [DE], et al) [YD] 1-3,6-14 * paragraph [0054]; claims 1,15 *;
 [A]  - BAEUERLE PATRICK A ET AL, "Bispecific T-cell engaging antibodies for cancer therapy.", CANCER RESEARCH 15 JUN 2009 LNKD- PUBMED:19509221, (20090615), vol. 69, no. 12, ISSN 1538-7445, pages 4941 - 4944, XP002665118 [A] 1-3,6-14

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-09-0547
 [AD]  - BAEUERLE PATRICK A ET AL, "BiTE: Teaching antibodies to engage T-cells for cancer therapy", CURRENT OPINION IN MOLECULAR THERAPEUTICS, THOMSON REUTERS (SCIETIFIC) LTD, (20090201), vol. 11, no. 1, ISSN 2040-3445, pages 22 - 30, XP009151509 [AD] 1-3,6-14
 [AD]  - BARGOU RALF ET AL, "Tumor regression in cancer patients by very low doses of a T cell-engaging antibody", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, (20080815), vol. 321, no. 5891, doi:10.1126/SCIENCE.1158545, ISSN 0036-8075, pages 974 - 977, XP002615656 [AD] 1-3,6-14

DOI:   http://dx.doi.org/10.1126/SCIENCE.1158545
 [YD]  - AL-EJEH F ET AL, "The La Autoantigen Is a Malignancy-Associated Cell Death Target That is Induced by DNA-Damaging Drugs", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20070915), vol. 13, no. 18, SUPPL, doi:10.1158/1078-0432.CCR-07-0922, ISSN 1078-0432, pages 5509S - 5518S, XP008105261 [YD] 1-3,6-14 * Abstract * Introduction * Discussion *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-07-0922
 [YD]  - AL-EJEH F ET AL, "In vivo Targeting of Dead Tumor Cells in a Murine Tumor Model Using a Monoclonal Antibody Specific for the La Autoantigen", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20070915), vol. 13, no. 18, SUPPL, doi:10.1158/1078-0432.CCR-07-0964, ISSN 1078-0432, pages 5519S - 5527S, XP008105259 [YD] 1-3,6-14 * Introduction * Discussion *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-07-0964
 [A]  - BACHMANN M ET AL, "Translocation of the nuclear autoantigen La to the cell surface of herpes simplex virus type 1 infected cells.", AUTOIMMUNITY 1992 LNKD- PUBMED:1617103, (1992), vol. 12, no. 1, ISSN 0891-6934, pages 37 - 45, XP009154578 [A] 1-3,6-14

DOI:   http://dx.doi.org/10.3109/08916939209146128
Examination   - KORISTKA STEFANIE ET AL, "Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B", JOURNAL OF AUTOIMMUNITY, LONDON, GB, (20130122), vol. 42, doi:10.1016/J.JAUT.2013.01.002, ISSN 0896-8411, pages 105 - 116, XP028531549

DOI:   http://dx.doi.org/10.1016/j.jaut.2013.01.002
    - WANG W W ET AL, "Antigen targeting to dendritic cells with bispecific antibodies", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 306, no. 1-2, ISSN 0022-1759, (20051130), pages 80 - 92, (20051130), XP027659256
    - SCHMITZ MARC ET AL, "Tumoricidal potential of native blood dendritic cells: Direct tumor cell killing and activation of NK cell-mediated cytotoxicity", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, (20050401), vol. 174, no. 7, ISSN 0022-1767, pages 4127 - 4134, XP002629625
    - PROSKURYAKOV SERGEY Y ET AL, "Mechanisms of tumor cell necrosis.", CURRENT PHARMACEUTICAL DESIGN JAN 2010, (201001), vol. 16, no. 1, ISSN 1873-4286, pages 56 - 68
    - B J Kroesen ET AL, "Bispecific antibodies for treatment of cancer in experimental animal models and man", Advanced Drug Delivery Reviews, (19980101), vol. 31, doi:10.1016/S0169-409X(97)00096-3, pages 105 - 129, XP055299943

DOI:   http://dx.doi.org/10.1016/S0169-409X(97)00096-3
    - CHAMES PATRICK ET AL, "Bispecific antibodies for cancer therapy. The light at the end of the tunnel?", MABS, LANDES BIOSCIENCE, US, (20091101), vol. 1, no. 6, doi:10.4161/MABS.1.6.10015, ISSN 1942-0862, pages 539 - 547, XP002688758

DOI:   http://dx.doi.org/10.4161/mabs.1.6.10015
    - GONZALEZ S ET AL, "NKG2D ligands: key targets of the immune response", TRENDS IN IMMUNOLOGY, ELSEVIER LTD. * TRENDS JOURNALS, GB, vol. 29, no. 8, doi:10.1016/J.IT.2008.04.007, ISSN 1471-4906, (20080801), pages 397 - 403, (20080703), XP023181111

DOI:   http://dx.doi.org/10.1016/j.it.2008.04.007
    - KUROKI MASAHIDE ET AL, "RE-TARGETING OF CYTOTOXIC T LYMPHOCYTES AND/OR NATURAL KILLER CELLS TO CEA-EXPRESSING TUMOR CELLS WITH ANTI-CEA ANTIBODY ACTIVITY", ANTICANCER RESEARCH - INTERNATIONAL JOURNAL OF CANCER RESEARCH AND TREAT, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, (20051101), vol. 25, no. 6A, ISSN 0250-7005, pages 3725 - 3732, XP009077768
    - MORETTA A ET AL, "ACTIVATING RECEPTORS AND CORECEPTORS INVOLVED IN HUMAN NATURAL KILLER CELL-MEDIATED CYTOLYSIS", ANNUAL REVIEW OF IMMUNOL, ANNUAL REVIEWS INC, US, (20010101), vol. 19, doi:10.1146/ANNUREV.IMMUNOL.19.1.197, ISSN 0732-0582, pages 197 - 223, XP008016880

DOI:   http://dx.doi.org/10.1146/annurev.immunol.19.1.197
    - PEIPP M ET AL, "Bispecific antibodies targeting cancer cells", BIOCHEMICAL SOCIETY TRANSACTIONS, PORTLAND PRESS LTD, GB, (20020101), vol. 30, doi:10.1042/BST0300507, ISSN 0300-5127, pages 507 - 511, XP002981328

DOI:   http://dx.doi.org/10.1042/BST0300507
    - Raja Rajalingam, "Human diversity of killer cell immunoglobulin-like receptors and disease", The Korean Journal of Hematology, (20110101), vol. 46, no. 4, doi:10.5045/kjh.2011.46.4.216, ISSN 1738-7949, page 216, XP055386149

DOI:   http://dx.doi.org/10.5045/kjh.2011.46.4.216
by applicantUS5457029
 US4751181
 US4784942
 WO2008043148
 US2005136050
    - SLE, MATTIOLI, M., REICHLIN, M., ARTHRITIS & RHEUMATISM, (1974), vol. 17, no. 4, pages 421 - 29
    - LSPAUGH, M. A., TAN, E. M., J CLIN INVEST, (1975), vol. 55, no. 5, pages 1067 - 73
    - GOTTLIEB, E. ET AL., EMBO J, (1989), vol. 8, no. 3, pages 841 - 50
    - CHAMBERS ET AL., J BIOL. CHEM., (1988), vol. 263, pages 18043 - 18051
    - MCNEILAGE ET AL., J CLIN. LAB. IMMUNOL., (1984), vol. 15, pages 1 - 17
    - CLIN. EXP. IMMUNOL., (1985), vol. 62, pages 685 - 695
    - ARTHRITIS RHEUM., (1999), vol. 42, no. 2, pages 199 - 209
    - CHAN EK ET AL., J EXP MED., (1987), vol. 166, no. 6, pages 1627 - 40
    - BACHMANN ET AL., EXP. CELL RES., (1990), vol. 191, pages 171 - 180
    - AUTOIMMUNITY, (1991), vol. 9, pages 99 - 107
    - AUTOIMMUNITY, (1992), vol. 12, pages 37 - 45
    - SMITH PR ET AL., J IMMUNOL METHODS., (1985), vol. 77, no. 1, pages 63 - 76
    - MAMULA MJ, J IMMUNOL, (1989), vol. 143, no. 9, pages 2923 - 8
    - OFFEN D ET AL., J AUTOIMMUN., (1990), vol. 3, no. 6, pages 701 - 13
    - BACHMANN ET AL., PNAS USA, (1986), vol. 83, pages 7770 - 7774
    - MAMULA ET AL., J IMMUNOL, (1989), vol. 143, no. 9, pages 2923 - 2928
    - LA CARMO-FONSECA ET AL., EXPCELLRES, (1989), vol. 185, no. 1, pages 73 - 85
    - TRÖSTER ET AL., J AUTOIMMUNITY, (1995), vol. 8, no. 6, pages 825 - 842
    - PRUIJN ET AL., EUR J BIOCHEM, (1995), vol. 232, pages 611 - 619
    - TRAN ET AL., ARTHRITIS RHEUM, (2002), vol. 46, no. 1, pages 202 - 208
    - AL EJEH ET AL., NUCL MED BIOL, (2009), vol. 36, no. 4, pages 395 - 402
    - AL-EJEH F ET AL., CLIN CANCER RES., (2007), vol. 13, pages 5509S - 5518S
    - AL-EJEH F ET AL., CLIN CANCER RES., (2007), vol. 13, pages 5519S - 5527S
    - AL-EJEH F ET AL., PLOS ONE., (2009), vol. 4, no. 2, page E4630
    - AL-EJEH F ET AL., PLOS ONE., (2009), vol. 4, no. 2, page E4558
    - P. A. BAEUERLE, "BiTE: Teaching antibodies to engage T cells for cancer therapy", CURR OPIN MOL THER, (2009), vol. 11, pages 22 - 30, XP009151509
    - R. BARGOU, "Tumor regression in cancer patients by very low doses of a T cell-engaging antibody", SCIENCE, (2008), vol. 321, doi:doi:10.1126/SCIENCE.1158545, pages 974 - 977, XP002615656

DOI:   http://dx.doi.org/10.1126/SCIENCE.1158545
    - K. BRISCHWEIN, "MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors", MOL IMMUNOL, (2006), vol. 43, doi:doi:10.1016/j.molimm.2005.07.034, pages 1129 - 1143, XP025037228

DOI:   http://dx.doi.org/10.1016/j.molimm.2005.07.034
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.